Access to orphan drugs in Europe: Current and future issues

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 1, 2012, Pages 23-29

  Michel, Morgane ^a   Toumi, Mondher ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

European Union; market access; marketing authorization; orphan drugs; price and reimbursement; regulation

Indexed keywords

ORPHAN DRUG;

CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PROGRAM; DRUG RESEARCH; EUROPE; EUROPEAN UNION; FUNDING; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HUMAN; PATIENT CARE; POSTMARKETING SURVEILLANCE; PRESCRIPTION; RESOURCE ALLOCATION; REVIEW;

DRUG COSTS; DRUG DESIGN; DRUG INDUSTRY; EUROPE; EUROPEAN UNION; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; ORPHAN DRUG PRODUCTION; RARE DISEASES; REIMBURSEMENT MECHANISMS;

EID: 84856487084     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.95     Document Type: Review

References (14)

1. European Commission: Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities L18/1-L18/5 (2000).
2. European Medicines Agency: fee reductions for designated orphan medicinal products. EMA/960144/2011. European Medicines Agency, London, UK (2011).
3. European Commission: guideline on aspects of the application of Article 8(2) of Regulation (EC) No. 141/2000: review of the period of market exclusivity of orphan medicinal products. Official Journal of the European Communities C242/8-C242/11 (2008).
4. EURORDIS position paper: why research on rare diseases? EURORDIS, Paris, France (2010).
5. European Commission: Council Directive 89/341/EEC of 3 May 1989 amending Directives 65/65/EEC, 75/318/EEC and 75/319/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products. Official Journal of the European Communities L142/11-L142/13 (1989).
6. Alcimed. Study on orphan drugs: Phase 1: overview of the conditions for marketing orphan drugs in Europe. Koning Boudewijnstichting 2006, 18-23 (2010).
7. Aballéa S, Toumi M, Vataire AL, Millier A, Lamure M. Quantitative analysis of the influence of disease and product characteristics on orphan drug prices in Europe. Presented at: 15th ISPOR International Meeting. Atlanta, GA, USA, 15-19 May 2010.
8. Le Cam Y. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & EURORDIS. EURORDIS, Paris, France (2010).
9. Picavet E, Dooms M, Cassiman D, Simoens S. Drugs for rare diseases: influence of orphan designation status on price. Appl. Health Econ. Health Policy 9(4), 275-279 (2011).
10. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet. J. Rare Dis. 6, 42 (2011).
11. European Commission: Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004. laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official Journal of the European Communities L136/1-L136/33 (2004).
12. Gliklich R, Leavy M. Patient registries and rare diseases. Appl. Clin. Trials 20(3) (2011).
13. Dear JW, Lilitkarntakul P, Webb DJ. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br. J. Clin. Pharmacol. 62, 264-271 (2006). (Pubitemid 44215525)
14. NICE. NICE Citizens Council Report: Ultra orphan drugs. NICE, London, UK (2004)